Management of bleeding disorders in children

Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden.
Haemophilia (Impact Factor: 2.6). 05/2012; 18 Suppl 2(s2):15-23. DOI: 10.1111/j.1365-2516.2012.02796.x
Source: PubMed


Haemophilia, if not properly managed, can lead to chronic disease and lifelong disabilities. The challenges and issues in infants/young children are different from those in older children and adults although episodes of bleeding still predominate as the diagnostic trigger. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitor development is a challenging complication of paediatric haemophilia and prophylaxis is emerging as the optimal preventive care strategy. In this section we will review some important aspects of haemophilia in children including early prophylaxis, current evidence relating to inhibitor development, including the aims of the SIPPET study which is already ongoing and involves boys <6 years, and the potential of immune tolerance therapy for eradicating the inhibitor and permitting a resumption of standard dosing schedules.

Download full-text


Available from: Susan Halimeh, May 25, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Assess the adequacy of the dosage of clotting factors for achieving plasma factor activity required in each patient based on analytical and pharmacokinetic parameters in patients with haemophilia undergoing major surgery. Method: Haemophilic patients without inhibitor who underwent major surgery between October 2009 and March 2010 were studied. Theoretical necessary dose of coagulation factor to maintain good coverage was calculated in every perioperative period depending on the type of haemophilia, the basal activity of the factor, the body weight, the plasmatic clearance of clotting factor, the clinical situation and the number of days after surgery of each patient. Results: Five patients with haemophilia A and one patient with haemophilia B were included. Patients with haemophilia A achieved a plasma factor activity more than 100%, before surgery and in the postoperative period (mean 154.7 ±35.02; 136.74 ±15.13% respectively). Factor units administered were higher than the theoretically required according to the basal activity of the factor and actual clearance in each patient, in presurgery period and postoperative period (8,125 and 98,330 IU respectively). Discussion: These data show that to maintain adequate haemostasis during surgery in these patients it would be advisable to consider the factor basal activity and its plasma clearance individually for each patient.
    No preview · Article · · Atencion Farmaceutica
  • [Show abstract] [Hide abstract]
    ABSTRACT: Haemophilia A and B are X-linked inherited bleeding disorders, characterized by a posttraumatic or spontaneous high tendency to bleeding and whose severity correlates with plasma levels of a specific coagulative factor. In therapeutic terms remarkable changes have been made about the greater availability of the missing factor (derived plasma and recombinant factor), so the effects of bleeding and formation of the haemarthroses can be reduced by adding the factor periodically in relation to the individual needs. One problem regarding the formation of antibodies that make the treatment ineffective still remains open.
    No preview · Article · Dec 2012 · Medico e Bambino
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immune tolerance induction (ITI) is recognized as the first choice treatment in haemophilic patients with inhibitors, with the aim of restoring safe and effective standard factor VIII replacement and, particularly, prophylaxis in children. For the latter, literature data and clinical practice support the optimal cost utility ratio of ITI. Indeed, the high success rate, the low incidence of inhibitor recurrence after successful ITI and the possibility of preventing joint deterioration, enable one to predict a considerable long-term reduction of costs in the majority of treated patients. Therefore, in spite of high costs and open issues about optimal regimens, ITI is actually attempted in virtually all children with inhibitors. Few patients with long-standing inhibitors presently undergo ITI, particularly in the case of severe bleeding tendency. In this setting, uncertainties concerning management are amplified by the paucity of literature data and psychological reluctance by both patients and treaters due to the perceived poor prognosis and the demanding treatment (also in terms of costs). However, clinical data suggest that the role of age at ITI start and of time interval from inhibitor diagnosis, as predictors of ITI outcome, should be considered in a larger framework of proposed and more established prognostic factors. Moreover, optimising ITI management, particularly with respect to inhibitor titre at ITI start and avoidance of adverse events or interruption of treatment, may also contribute to improve outcomes. Although the economic constraints of the present era significantly affect resources for such a high-cost treatment, the individual cost-utility ratio (bleeding tendency and risk of fatal bleeding, arthropathy and need for orthopaedic surgery, comorbidities, quality of life) should be assessed carefully to determine whether ITI is a suitable option and thus not preclude adults from the opportunity of inhibitor eradication.
    No preview · Article · Jan 2013 · Haemophilia
Show more